ArticleAsian journal of transfusion science
Comparison of diagnostic performance of transcription-mediated amplification with chemiluminescent microparticle immunoassay in the detection of hepatitis C virus in dialysis patient group.
Article in Asian journal of transfusion science. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThe aim of the study was to demonstrate that ID-NAT is more sensitive and specific in HCV detection in dialysis patients than serological tests such as chemiluminescence. Second, to establish that ID-NAT results are more in concordance to gold standard RT-PCR compared to chemiluminescence. MATERIALS AND
methodA prospective observational single center study conducted in the Department of Transfusion Medicine and Immunohematology and Department of Nephrology, Indraprastha Apollo Hospital, New Delhi from September 2020 to December 2022. The blood samples from patients within inclusion criteria were run with chemiluminescence, ID-NAT and RT-PCR. Results were analyzed to determine the association between categorical variables and Cohen kappa values, to show the concordance between the gold standard and the ID-NAT and RT-PCR.
resultsThe total number of subjects who participated in the study was n = 145 and were all Indians from neighboring states near to the institution. As reflected in the study results, among the 130 non-reactive results in CMIA, PCR showed 127 negative and 3 positive results. In similar manner, among 15 reactive results in CMIA, 13 were positive and 2 were negative in PCR (p value 0.001). In the present study, it was revealed that among the 129 non-reactive results in ID-NAT, 129 were negative in PCR (P value <0.001). Prevalence of HCV among patients with ID-NAT was 11.03% (CI = 6.44% to 17.30%). Similarly, the agreement of chemiluminescence with RT-PCR revealed kappa value = 0.819, whereas ID-NAT showed kappa value = 1, thus showing superior concordance to said gold standard.
conclusionThe study results confirm that ID-NAT is a more efficient and reliable test method compared to serological tests such as chemiluminescence in detecting HCV cases in immunosilent cases or cases in the immune period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.